GlassScriptPhysician profile
Ernesto Pena-Tejeda
NPI 1619758620
$1,077.54
in general payments reported to CMS, 2019-2025
9 companies · $989 in 2025
The $989 reported for 2025 was more than what 89% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $18.10 · 2024: $70.15 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $736 · Food and Beverage: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $736.17 |
| Food and Beverage | $341.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $776.88 | 2025 | Micromatrix, Integra, Integra Dermal Regeneration Template |
| Smith+Nephew, INC. | $147.27 | 2024-2025 | Renasys Touch, Collagenase Santyl |
| Merck Sharp & Dohme LLC | $32.66 | 2023-2024 | Verquvo |
| Vertex Pharmaceuticals Incorporated | $26.83 | 2025 | |
| Corcept Therapeutics | $22.73 | 2025 | Korlym |
| Solventum Corporation | $18.64 | 2025 | Prevena, V.A.C.Ulta |
| Dexcom, INC. | $18.62 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.92 | 2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $15.99 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernesto Pena-Tejeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.